Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke

(MedPage Today) — NEW ORLEANS — Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but without a history of myocardial…